David Nierengarten
Stock Analyst at Wedbush
(3.72)
# 757
Out of 4,984 analysts
200
Total ratings
46.34%
Success rate
8.91%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVB Nuvation Bio | Reiterates: Outperform | $6 | $3.24 | +85.19% | 10 | Sep 8, 2025 | |
| NUVL Nuvalent | Reiterates: Outperform | $115 | $79.92 | +43.89% | 6 | Sep 8, 2025 | |
| STTK Shattuck Labs | Initiates: Outperform | $4 | $2.05 | +94.99% | 1 | Sep 8, 2025 | |
| XNCR Xencor | Reiterates: Outperform | $26 | $9.75 | +166.67% | 8 | Sep 2, 2025 | |
| TLX Telix Pharmaceuticals | Reiterates: Outperform | $22 | $9.26 | +137.58% | 3 | Aug 28, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Outperform | $25 | $12.00 | +108.33% | 1 | Aug 18, 2025 | |
| GBIO Generation Bio Co. | Downgrades: Neutral | $7 | $5.85 | +19.76% | 9 | Aug 13, 2025 | |
| VOR Vor Biopharma | Reiterates: Neutral | $0.4 | $1.48 | -72.88% | 8 | Jun 26, 2025 | |
| ARGX argenx SE | Reiterates: Outperform | $715 | $730.06 | -2.06% | 21 | Jun 24, 2025 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $3.26 | +237.42% | 4 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $14.66 | -31.79% | 10 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $27 | $12.87 | +109.79% | 8 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $34 | $35.59 | -4.47% | 3 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 | $9.29 | +255.22% | 6 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $0.86 | +132.21% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.00 | +400.00% | 15 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $11.00 | +181.82% | 2 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $20.39 | +96.17% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $87 → $90 | $38.20 | +135.60% | 3 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $31.50 | +49.21% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $10.81 | +85.01% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $16.16 | +147.52% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $15.22 | +195.66% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.64 | +509.76% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $2.34 | +669.23% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $61.26 | -6.95% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $12.41 | -19.42% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $5.14 | +133.46% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $24.32 | +134.38% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $50 → $175 | $7.35 | +2,280.95% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $3.73 | +13,304.83% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $6.06 | +890.10% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $8.79 | +116.15% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $28.76 | +160.78% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.14 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $4.38 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.16 | - | 3 | Nov 20, 2017 |
Nuvation Bio
Sep 8, 2025
Reiterates: Outperform
Price Target: $6
Current: $3.24
Upside: +85.19%
Nuvalent
Sep 8, 2025
Reiterates: Outperform
Price Target: $115
Current: $79.92
Upside: +43.89%
Shattuck Labs
Sep 8, 2025
Initiates: Outperform
Price Target: $4
Current: $2.05
Upside: +94.99%
Xencor
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $9.75
Upside: +166.67%
Telix Pharmaceuticals
Aug 28, 2025
Reiterates: Outperform
Price Target: $22
Current: $9.26
Upside: +137.58%
BridgeBio Oncology Therapeutics
Aug 18, 2025
Initiates: Outperform
Price Target: $25
Current: $12.00
Upside: +108.33%
Generation Bio Co.
Aug 13, 2025
Downgrades: Neutral
Price Target: $7
Current: $5.85
Upside: +19.76%
Vor Biopharma
Jun 26, 2025
Reiterates: Neutral
Price Target: $0.4
Current: $1.48
Upside: -72.88%
argenx SE
Jun 24, 2025
Reiterates: Outperform
Price Target: $715
Current: $730.06
Upside: -2.06%
Perspective Therapeutics
Jun 23, 2025
Reiterates: Outperform
Price Target: $11
Current: $3.26
Upside: +237.42%
May 19, 2025
Reiterates: Neutral
Price Target: $10
Current: $14.66
Upside: -31.79%
Apr 16, 2025
Maintains: Neutral
Price Target: $29 → $27
Current: $12.87
Upside: +109.79%
Apr 16, 2025
Reiterates: Outperform
Price Target: $34
Current: $35.59
Upside: -4.47%
Mar 20, 2025
Reiterates: Outperform
Price Target: $33
Current: $9.29
Upside: +255.22%
Mar 14, 2025
Downgrades: Neutral
Price Target: $8 → $2
Current: $0.86
Upside: +132.21%
Mar 6, 2025
Reiterates: Neutral
Price Target: $5
Current: $1.00
Upside: +400.00%
Feb 12, 2025
Reiterates: Outperform
Price Target: $31
Current: $11.00
Upside: +181.82%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $20.39
Upside: +96.17%
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $38.20
Upside: +135.60%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $31.50
Upside: +49.21%
Sep 10, 2024
Reiterates: Outperform
Price Target: $20
Current: $10.81
Upside: +85.01%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $16.16
Upside: +147.52%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $15.22
Upside: +195.66%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.64
Upside: +509.76%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $2.34
Upside: +669.23%
Aug 9, 2024
Reiterates: Outperform
Price Target: $57
Current: $61.26
Upside: -6.95%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $12.41
Upside: -19.42%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $5.14
Upside: +133.46%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $24.32
Upside: +134.38%
Feb 29, 2024
Upgrades: Outperform
Price Target: $50 → $175
Current: $7.35
Upside: +2,280.95%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $3.73
Upside: +13,304.83%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $6.06
Upside: +890.10%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $8.79
Upside: +116.15%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $28.76
Upside: +160.78%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.14
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $4.38
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $8.16
Upside: -